In early September, the Croatian pharmaceutical company PharmaS successfully completed the acquisition process of a majority stake in the Spanish Mabo Farma, headquartered in Madrid, thereby taking over the management of the company.
The statement notes that Mabo Farma is the fastest-growing generic company in Spain, with a portfolio of over 200 products, primarily prescription medications, but also over-the-counter (OTC) drugs and dietary supplements. This pharmaceutical company generates an annual revenue of approximately 35 million euros with more than 70 employees.
One of Mabo Farma’s main strengths is its exceptional knowledge of the Spanish market and a wide sales network with over forty sales representatives covering the entire territory of Spain, including the Balearic Islands and Tenerife.
With this international acquisition, in addition to expanding its portfolio and confirming itself as one of the strongest domestic pharmaceutical companies, PharmaS opens the doors to the Spanish market for its own domestic products, which will soon be available on the shelves of Spanish pharmacies.
– Entering the Spanish market marks the beginning of our five-year strategic plan, aimed at expanding into new markets in Western Europe and continuing to build PharmaS as a strong international player in the field of prescription and over-the-counter medications, as well as dietary supplements. For our employees, this is an opportunity to gain important international experience. What particularly excites us is that we will soon see Croatian products on the shelves across Spain. Furthermore, this demonstrates the strength and strategic importance of the entire pharmaceutical industry in Croatia, which generates more than 70 percent of its revenue through exports to around 60 countries worldwide – said Jerko Jakšić, CEO of PharmaS.
